InCarda Therapeutics to Present Preliminary Phase 2 Data at American Heart Association 2020 Scientific Sessions (Nov. 13-17, 2020)

On Friday, November 13 at 9:00am CT/10:00am ET, Dr. Harry Crijns, Clinical Electrophysiologist from Maastricht University Medical Center in the Netherlands, will present data from the open-label, dose-escalation Part A portion of InCarda’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in patients with recent-onset paroxysmal atrial fibrillation (PAF).

The poster presentation is entitled “An Open-label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution Shows Acute Conversion of Recent-onset, Symptomatic Atrial Fibrillation to Sinus Rhythm in a Dose- and Concentration-dependent Manner” and is included in the AHA session entitled “Anti Arrhythmic Drug Considerations in 2020.”

Fore more information on the AHA 2020 Scientific sessions:  https://professional.heart.org/es/meetings/scientific-sessions